Short Communication Open Access
Methods for including patient preferences into the risk and benefit decisions of the Food and Drug Administration for drugs and devices: The input of behavioral economics
Abstract
Problem Statement: The Food and Drug Administration has historically made approval decisions for new devices without
meaningful patient input. Individual patients experience effects of diseases and therapies differently and their trade-offs between
therapy risks and benefits may differ from their healthcare provider or FDA. In 2016 an FDA guidance was released to include
patient preference information into device submissions. Behavioral economics and utility theory offer multiple methods to
measure patients’ preferences for risks and benefits of treatments, yet FDA is uncertain which methods are best for approval
decisions. This study purpose is to describe the current status of patient preference measurement in FDA and present our
approach to development and validating different conceptual measurement methods for new prosthetic devices for patients
with limb loss. Methodology and Theoretical Orientation: A modified meta-ethnographic approach, including concept synthesis,
interviews and pilot testing were used to develop 2 methodologically different patient preference measures; choice-based conjoint
(CBC) and a standard gamble (SG) utility method. We describe development and compare responses of the three different
approaches in 20 subjects with upper limb loss. Findings: There was variability across our subjects in reason and level of limb
loss, age, time with limb loss and prosthetic experience. The method of attribute selection led to the need for video use to better
describe the beneficial motion of new prosthetics. Patients showed a stronger preference for favoring benefits and ignoring risks
when preferences were measured using video, but all methods demonstrated consistency in preferences across attributes of risk
and benefit. Conclusion and Significance: Persons with upper limb loss were able to make trade-offs in decisions using risks and
benefits of two new innovations in prosthetic devices. The FDA will be able to use our results validating the best methods to use,
to update their guidance on patient preference methods.
Leslie Wilson
To read the full article Download Full Article